Company: DMAAR
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076681
Chunk: 58

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 58
---
 have agreed (and their permitted transferees will agree), pursuant to the
terms of a letter agreement, to vote any shares held by them in favor of the initial Business Combination.

6

DRUGS MADE IN AMERICA ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

JUNE 30, 2025

(Unaudited)

The underwriters have agreed to waive their rights
to their deferred underwriting commissions (see Note 6) held in the Trust Account in the event the Company does not complete a Business
Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account
that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share
value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

The Company will have until 15 months
from the closing of the Initial Public Offering (April 29, 2026) to complete a Business Combination. However, if the Company is unable
to complete the initial Business Combination within 15 months from the closing the Initial Public Offering, the time period to complete
an initial Business Combination can be extended without shareholder approval up to two times, each by an additional three months
(for a total of up to 21 months to complete an initial Business Combination) (the “Combination Period”), subject to the
Sponsor depositing into the Trust Account $0.10 per public share outstanding in connection with each such extension. If the Company
has not completed a Business Combination within the Combination Period, the Company will (i) cease all operations except for the
purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the
public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest
earned on the funds held in the Trust Account (net of funds withdrawn to pay taxes, if any, and up to $100,000 of interest to pay dissolution
expenses), divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public shareholders’
rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably
possible following such redemption, subject